Category: Dosificacion y farmacocinética


REFERENCIAS BIBLIOGRÁFICAS

1. Castellanos A, Rodríguez N, García R, et al: Antibióticos. Bol. Hosp. Niños; 1996; 32(3): 11-30.

2. Baldo BA. Penicillins and cephalosporins as allergens – structural aspects of recognition and cross – reactions. Clin Exp Allergy; 1999; 29 (6): 744-9.

3. Jawetz E. Penicilinas y cefalosporinas (Katzung, B. Editor). En: Farmacología Básica y Clínica. 6ª edición. Editorial El Manual Moderno, S.A de C.V. México 1996; 829-843.

4. Velasco J, Gutierrez S, Fernández FJ, et al. Exogenous methionine increases levels of mRNAs transcribed from cephalosporin biosynthetic pathway, in Acremonium chrysogenum. J Bacteriol; 1994; 176 (4): 985-91.

5. Ishida Y, Miyazaki S, Yamaguchi K, et al. In vitro and in vivo activity of DQ 2556, a new cephalosporin. Chemotherapy; 1995; 41(1): 5-13.

6. Mandell G, Petri W. Fármacos antimicrobianos: penicilinas, cefalosporinas y otros antibióticos beta-lactámicos. En: Las Bases Farmacológicas de la Terapéutica (Molinoff, P y Ruddon, R. Eds). 9ª Edición. McGraw-Hill Interamericana. 1996; 1141-1156.

7. Degnan R. Antibiotics. RN. 1997; 60(10): 49-53.

8. Neu HC. The new beta-lactamase-stable cephalosporins. Ann Intern Med; 1982; 97: 408-11.

9. Ross-Flanigan N. Cephalosporins. Gale Encyclopedia of Medicine, Edition 1. 1999; 623-4.

10. Pocket Pharmacopoeia. The 1999 Tarascon. Tarascon Publishing. USA. p 16-9.

11. Barnett ED, Teele DW, Klein JO, et al. Comparison of Ceftriaxone and Trimethoprim – sulfamethoxazole for acute otitis media. Greater Boston Otitis Media Study Group. Pediatrics. 1997; 99(1): 23-8.

12. De Klerk GJ, Van Steijn JH, Lobatto S, et al. A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections, int. J Antimicrob Agents. 1999; 12(2): 121-7.

13. Krumpe P, Lin CC, Radwanski E, et al. The penetration of ceftibuten into the respiratory tract. Journal Announcement. 1999; 116(2): 369-74.

14. Harvey RA, Champe PC, et al. Lippincott’s Illustrated Reviews: Pharmacology. J.B. Lippincott Company. Philadelphia. 1992; 279-81.

15. Mayer I, Nagy E. Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas sp. Journal Announcement. 1999; 43(5): 651-7.

16. Tessier PR, Nicolav DP, Onyeji, et al. Pharmacodynamics of intermitt -and continous- infusion cefepime alone and in combination with once daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Chemotherapy. 1999; 45(4): 284-295.

17. Pichichero ME. Group A streptococcal tonsillopharyngitis: cost-effective diagnosis and treatment. Ann Emerg Med; 1995; 25(3): 404-6.

18. Albrecht HA, Beskid G, Christenson JG, et al. Dual – action cephalosporins incorporating a 3’ – tertiary – amine – linked quinolone. J Med Chem. 1994; 37(3): 400-7.

19. Bal C. Increasing antimicrobial resistance in STDs and the need for surveillance: Neisseria gonorrhoeae as a model. Immunol Med Microbiol; 1999; 24(4): 447-53.

20. Jawetz E, Melnick J, adelberg E, et al. Microbiología Médica. 13va edición. Editorial Manual Moderno. México. 1990; 161-3.

21. Landesman SH, Corrado MS, Shah PM, et al. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Am J. Med; 1981; 71: 693-703.

22. Tierney LM, McPhee SJ, Papadakis MA. Current, Medical Diagnosis ant Treatment. 37th edition. Appleton and Lange, USA. 1998; 1413-17.

23. Gainer RB 2nd. Cefprozil, a new cephalosporin: its use in various clinical trials. South Med J. 1995; 88(3): 338-46.

24. Marchetti B. In vitro activity of ceftazidime, cepepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolated either susceptible or resistant to beta-lactams. Chemotherapy. 2000; 46(4): 229-234.

25. Rouzzi A, Khalifa B, Al-Hamdan H and Bondagji N. The routine use of cefazolin in cesarean section. Int. J Gynaecol. Obstet. 2000; 69(2): 107-112.

Nombre Dosis Vida Media (min) Niveles en plasma (mg/ml) * Bd (%) UP (%)
Adultos Niños
Cefalotina 0.5-1 gr c/4-6 hr. 80-160 mg/kg/d c/4-6 hr. 30-40 6-21 20-30 70
Cefazolina 1-2 gr TID 20 mg/kg/d TID 120 64 0 80-84
Cefalexina (1) 1-4 gr QID 25-50 mg/kg/d c/6-12 hr 50 8-30 Alta 20
Cefradina (1) 2-4 gr c/4 hr IM-IV 25-50 mg/kg/d QID, IV, IM, VO 18-46 16-86 >90 <15
Cefadroxilo (1) 1-2 gr BID 30-50 mg/kg/d BID 60-90 15 Elevada 20
Cefamandol 0.5-1 gr c/4-8 hr 50-100 mg/kg/d c/4-8 hr (En infecciones severas 150 mg/kg/d) 30-60 13-25 - 56-78
Cefoxitina 1-2 gr c/4-6 hr 80-100 mg/kg/d TID o QID 40 60-80 Buena -
Ceftriaxone 1-2 gr qd Gonorrea DU 125 mg IM 50-75 mg/kg/d qd o BID (100 mg/kg/d para meningitis) 500 43-75 0 90-95
Cefixime 400 mg qd ó 200 BID 8 mg/kg/d qd o BID 180-240 35 40-50 -
Ceftibuten (1) 400 mg qd 9 mg/kg/d qd 120 20 75-90 <25
Cefdinir 600 mg qd ó 300 mg BID 14 mg/kg/d qd ó 7 mg/kg/d BID 102 - 20-25 >70
Cefuroxime 750-1500 mg IV/CM TID 250-500 mg TID 250-500 mg/kg/d BID VO 50-100 mg/kg/d IV c/6-8 hr 80 80-100 buena -
Cefaclor (1) 250-500 mg TID 20-40 mg/kg/d BID o TID 30-60 7-13 50 25
Locacarbef (1) 200-400 mg BID 15-30 mg/kg/d BID 60 10 Media -
Cefprozil 250-500 mg qd o BID 15 mg/ kg/ dosis BID 90 10 90 -
Cefonocid 1-2 gr qd - 240 200-250 - -
Cefotetan 1-2 gr BID - 180 60-80 - -
Ceftazidime 1 gr IV/IM ó 2 gr IV c/8-12 hr 30-50 mg/kg/d TID 120 100-120 Alta Baja
Cefotaxime 1-2 gr c/6-8 hr 30-50 mg/kg/d c/6-8 hr 75 13-21 100 35
Cefpodoxima axetil (1) 200-800 mg BID 10 mg/kg/d BID 150 2 Alta -
Ceftizoxime 1-2 gr IV c/8-12 hr 50 mg/ kg/ dosis IV c/6-8 hr 100 80-100 Alta -
Cefoperazone 2-4 gr BID - 120 150 Alta -
Moxalactam 500-200 mg/kg/d c/6-12 hr - 120 6-100 - -
Cefepime 0.5-2 gr BID - 120 126-193 >80 -
Después de la administración de 1 gr. IV / IM.
Bd: biodisponibilidad
(1) Basado en 0.5 g dosis oral.

 

Seguir

Recibe cada nueva publicación en tu buzón de correo electrónico.